Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial

BACKGROUND: Normofractionated radiation regimes for definitive prostate cancer treatment usually extend over 7–8 weeks. Recently, moderate hypofractionation with doses per fraction between 2.2 and 4 Gy has been shown to be safe and feasible with oncologic non-inferiority compared to normofractionati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ristau, J., Hörner-Rieber, J., Buchele, C., Klüter, S., Jäkel, C., Baumann, L., Andratschke, N., Garcia Schüler, H., Guckenberger, M., Li, M., Niyazi, M., Belka, C., Herfarth, K., Debus, J., Koerber, S. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011377/
https://www.ncbi.nlm.nih.gov/pubmed/35428327
http://dx.doi.org/10.1186/s13014-022-02047-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011377/
https://www.ncbi.nlm.nih.gov/pubmed/35428327
http://dx.doi.org/10.1186/s13014-022-02047-w

Ejemplares similares